Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells

BMC Cancer

Thoralf Christoffersen²  Dagny L Sandnes²  John Ødegård²  Monica Aasrum²  Ingun H Tveteraas²  Ingvild J Brusevold¹ 

[1]Department of Oral biology, Faculty of Dentistry, University of Oslo, Oslo, Norway

[2]Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, and Oslo University Hospital, Blindern, P.O. Box 1057, Oslo N-0316, Norway

关键词: Coculture;    Invasion;    Cell migration;    LPA receptors;    Lysophosphatidic acid;    Epidermal growth factor receptor;    Carcinoma;   

Others  :  1125379
DOI  :  10.1186/1471-2407-14-432

 received in 2013-12-05, accepted in 2014-06-03,  发布年份 2014

【 摘 要 】

Background

Oral squamous cell carcinoma is an aggressive neoplasm with serious morbidity and mortality, which typically spreads through local invasive growth. Lysophosphatidic acid (LPA) is involved in a number of biological processes, and may have a role in cancer cell migration and invasiveness. LPA is present in most tissues and can activate cells through six different LPA receptors (LPAR1-6). Although LPA is predominantly promigratory, some of the receptors may have antimigratory effects in certain cells. The signalling mechanisms of LPA are not fully understood, and in oral carcinoma cells the specific receptors and pathways involved in LPA-stimulated migration are unknown.

Methods

The oral carcinoma cell lines E10, SCC-9, and D2 were investigated. Cell migration was studied in a scratch wound assay, and invasion was demonstrated in organotypic three dimensional co-cultures. Protein and mRNA expression of LPA receptors was studied with Western blotting and qRT-PCR. Activation of signalling proteins was examined with Western blotting and isoelectric focusing, and signalling mechanisms were further explored using pharmacological agents and siRNA directed at specific receptors and pathways.

Results

LPA stimulated cell migration in the two oral carcinoma cell lines E10 and SCC-9, but was slightly inhibitory in D2. The receptor expression profile and the effects of specific pharmacological antagonist and agonists indicated that LPA-stimulated cell migration was mediated through LPAR3 in E10 and SCC-9. Furthermore, in both these cell lines, the stimulation by LPA was dependent on PKC activity. However, while LPA induced transactivation of EGFR and the stimulated migration was blocked by EGFR inhibitors in E10 cells, LPA did not induce EGFR transactivation in SCC-9 cells. In D2 cells, LPA induced EGFR transactivation, but this was associated with slowing of a very high inherent migration rate in these cells.

Conclusion

The results demonstrate LPA-stimulated migration in oral carcinoma cells through LPAR3, mediated further by PKC, which acts either in concert with or independently of EGFR transactivation.

【 授权许可】

   
2014 Brusevold et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Sano D, Myers J: Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007, 26(3):645-662.
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [3]Ziober AF, Falls EM, Ziober BL: The extracellular matrix in oral squamous cell carcinoma: friend or foe? Head Neck 2006, 28(8):740-749.
• [4]Leemans CR, Braakhuis BJM, Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11(1):9-22.
• [5]Allen M, Jones JL: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011, 223(2):162-176.
• [6]Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9(4):239-252.
• [7]Roussos ET, Condeelis JS, Patsialou A: Chemotaxis in cancer. Nat Rev Cancer 2011, 11(8):573-587.
• [8]Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2010, 141(7):1117-1134.
• [9]Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284(1):31-53.
• [10]Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006, 24(17):2666-2672.
• [11]Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12):915-925.
• [12]Brusevold IJ, Aasrum M, Bryne M, Christoffersen T: Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med 2012, 41(7):547-558.
• [13]Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3(9):639-650.
• [14]Cotton M, Claing A: G protein-coupled receptors stimulation and the control of cell migration. Cell Signal 2009, 21(7):1045-1053.
• [15]Katritch V, Cherezov V, Stevens RC: Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 2013, 53:531-556.
• [16]Lappano R, Maggiolini M: G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011, 10(1):47-60.
• [17]Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A: Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997, 16:7032-7044.
• [18]Pierce KL, Luttrell LM, Lefkowitz RJ: New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001, 20(13):1532-1539.
• [19]Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T: Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J Cell Physiol 2008, 214(2):371-380.
• [20]Muller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood M, Dajani O, Christoffersen T, Sandnes DL: Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer 2011, 11:421. BioMed Central Full Text
• [21]Tveteraas IH, Muller KM, Aasrum M, Odegard J, Dajani O, Guren T, Sandnes D, Christoffersen T: Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res 2012, 31:72. BioMed Central Full Text
• [22]Houben AS, Moolenaar W: Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 2011, 30(3–4):557-565.
• [23]Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J: LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010, 50:157-186.
• [24]Okudaira S, Yukiura H, Aoki J: Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010, 92(6):698-706.
• [25]George J, Headen KV, Ogunleye AO, Perry GA, Wilwerding TM, Parrish LC, McVaney TP, Mattson JS, Cerutis DR: Lysophosphatidic acid signals through specific lysophosphatidic acid receptor subtypes to control key regenerative responses of human gingival and periodontal ligament fibroblasts. J Periodontol 2009, 80(8):1338-1347.
• [26]Hwang YS, Lee SK, Park K-K, Chung W-Y: Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. Oral Oncol 2012, 48(1):40-48.
• [27]Gschwind A, Prenzel N, Ullrich A: Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002, 62(21):6329-6336.
• [28]Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, Uchiyama A, Murakami-Murofushi K, Kennel S, Wall J, Patil R, Gupte R, Balasz L, Miller DD, Tigyi GJ: Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 2012, 40(1):31-36.
• [29]Jongsma M, Matas-Rico E, Rzadkowski A, Jalink K, Moolenaar WH: LPA Is a Chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One 2011, 6(12):e29260.
• [30]Fischer OM, Hart S, Gschwind A, Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003, 31(Pt 6):1203-1208.
• [31]Brusevold IJ, Husvik C, Schreurs O, Schenck K, Bryne M, Soland TM: Induction of invasion in an organotypic oral cancer model by CoCl2, a hypoxia mimetic. Eur J Oral Sci 2010, 118(2):168-176.
• [32]O'Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J, Gentalen E, Glazer M, Gossett J, Hacker K, Kirby C, Knittle J, Loder R, Mastrioeni C, MacLaren M, Mills T, Nguyen U, Parker N, Rice A, Roach D, Suich D, Voehringer D, Voss K, Yang J, Yang T, Horn PBV: Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci U S A 2006, 103(44):16153-16158.
• [33]Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL: Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012, 13:134. BioMed Central Full Text
• [34]Yanagida K, Kurikawa Y, Shimizu T, Ishii S: Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta 2013, 1831(1):33-41.
• [35]Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL, Lynch KR: Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 2001, 60(6):1173-1180.
• [36]Griner EM, Kazanietz MG: Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007, 7(4):281-294.
• [37]Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY: Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J 2009, 23(2):425-432.
• [38]Do T-V, Symowicz JC, Berman DM, Liotta LA, Petricoin EF, Stack MS, Fishman DA: Lysophosphatidic acid down-regulates stress fibers and up-regulates pro–matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res 2007, 5(2):121-131.
• [39]Lin ME, Herr DR, Chun J: Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010, 91(3–4):130-138.
• [40]Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im D-S, Nochi H, Tamoto K, Tomura H, Okajima F: Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003, 64(4):994-1005.
• [41]Snider AJ, Zhang Z, Xie Y, Meier KE: Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation. Am J Physiol Cell Physiol 2010, 298(1):C163-C170.
• [42]Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X: Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 2003, 278(14):11962-11969.
• [43]Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD: Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem 2003, 46(26):5575-5578.
• [44]Anliker B, Chun J: Lysophospholipid G protein-coupled receptors. J Biol Chem 2004, 279(20):20555-20558.
• [45]Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB: Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008, 100(22):1630-1642.
• [46]Cai H, Xu Y: The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 2013, 11(1):31. BioMed Central Full Text
• [47]Fukui R, Tanabe E, Kitayoshi M, Yoshikawa K, Fukushima N, Tsujiuchi T: Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells. Tumour Biol 2012, 33:1899-1905.
• [48]Kim JH, Adelstein RS: LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol 2011, 226(11):2881-2893.
• [49]Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, Kimura T, Kuwabara A, Ohta H, Im D-S, Kurose H, Takeyoshi I, Sato K, Okajima F: LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 2009, 30(3):457-465.
• [50]Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY: Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011, 30(11):1351-1359.
• [51]Harma V, Knuuttila M, Virtanen J, Mirtti T, Kohonen P, Kovanen P, Happonen A, Kaewphan S, Ahonen I, Kallioniemi O, Grafstrom R, Lotjonen J, Nees M: Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene 2012, 31(16):2075-2089.
• [52]Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA: LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol 2009, 112(1):215-223.
• [53]Chen M, Towers LN, O'Connor KL: LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 2007, 292(5):C1927-C1933.
• [54]Matayoshi S, Chiba S, Lin Y, Arakaki K, Matsumoto H, Nakanishi T, Suzuki M, Kato S: Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells. Int J Oncol 2013, 42(5):1560-1568.
• [55]Lee Z, Cheng C-T, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen C-K, Fang X: Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008, 19(12):5435-5445.
• [56]Harper K, Arsenault D, Boulay-Jean S, Lauzier A, Lucien F, Dubois CM: Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: Participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res 2010, 70(11):4634-4643.
• [57]Sokolov E, Eheim AL, Ahrens WA, Walling TL, Swet JH, McMillan MT, Simo KA, Thompson KJ, Sindram D, McKillop IH: Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma. J Surg Res 2013, 180(1):104-113.